NACI recommendations on the use of LAIV and HIV-infected individuals

PDF

"The objective of this advisory committee statement is to review the evidence for efficacy, effectiveness, immunogenicity and safety for LAIV use in HIV-infected individuals and to provide updated guidance on the use of LAIV in this population." - NACI recommendations on the use of LAIV and HIV-infected individuals

Download

Related Resources

Bookmark

Implementation Tool

PDF

Author: Dorothy L Moore, Ian Gemmill, Robyn Harrison Published: 2020 Region: National Audience: Health Care Professional Product Type: Guide Language: English Population: Children (All), High Risk Children Organization: Public Health Agency of Canada (PHAC) Publication: Canada Communicable Disease Report (CCDR)

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.

NACI recommendations on the use of LAIV and HIV-infected individuals

Implementation Tool

Category

0 Comments

Make the most of the CANVax community. Join today!

The Canadian Vaccination Evidence Resource and Exchange Centre (CANVax)

NACI recommendations on the use of LAIV and HIV-infected individuals

Implementation Tool

Category

0 Comments

Autism Society of America’s Guide to Accessible Vaccine Clinics

Summary of National Advisory Committee on Immunization (NACI) Statement of June 29, 2022 : Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada

Summary of National Advisory Committee on Immunization (NACI) Statement of July 14, 2022 : Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age

Monkeypox: Vaccination clinic resources

Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022

National Advisory Committee on Immunization (NACI) : Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada

An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age

COVID-19 Vaccine After - Care Sheet Children (Ages 5 -11)

Seasonal Influenza Program Package 2021-2022

Create an account

Create an account

Resource Rating Breakdown

The Canadian Vaccination Evidence Resource and Exchange Centre (CANVax)